Dr. Shannon Westin, MD
Claim this profileM D Anderson Cancer Center
Expert in Ovarian Cancer
Studies Fallopian Tube Cancer
23 reported clinical trials
39 drugs studied
Area of expertise
1Ovarian Cancer
Global LeaderStage IV
BRCA positive
Stage III
2Fallopian Tube Cancer
Stage IV
BRCA positive
Stage III
Affiliated Hospitals
Clinical Trials Shannon Westin, MD is currently running
Selumetinib + Olaparib
for Ovarian and Endometrial Cancer
This phase II ComboMATCH treatment trial compares selumetinib plus olaparib to selumetinib alone in women with endometrial or ovarian (fallopian tube and primary peritoneal) cancer that has come back (recurrent) or that remains despite treatment (persistent) and harbors a mutation in the RAS pathway. Selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Olaparib is an inhibitor of PARP, an enzyme that helps repair deoxyribonucleic acid (DNA) when it becomes damaged. Blocking PARP may help keep tumor cells from repairing their damaged DNA, causing them to die. PARP inhibitors are a type of targeted therapy. The addition of olaparib to selumetinib could increase the percentage of tumors that shrink as well as lengthen the time that the tumors remain stable (without progression) as compared to selumetinib alone.
Recruiting1 award Phase 2
BP1001-A + Paclitaxel
for Solid Tumors
This is a phase I, open-label, study of BP1001-A in participants with advanced or recurrent solid tumors. The dose escalation phase will determine the safety and the maximum tolerated dose (MTD) or maximum administered dose (MAD) of BP1001-A as a single agent. After the MTD or MAD of BP1001-A is established, the dose expansion phase will commence and determine the safety, toxicity and response of BP1001-A in combination with paclitaxel.
Recruiting1 award Phase 117 criteria
More about Shannon Westin, MD
Clinical Trial Related6 years of experience running clinical trials · Led 23 trials as a Principal Investigator · 3 Active Clinical TrialsTreatments Shannon Westin, MD has experience with
- Olaparib
- Paclitaxel
- Carboplatin
- Bevacizumab
- Durvalumab
- Adavosertib
Breakdown of trials Shannon Westin, MD has run
Ovarian Cancer
Fallopian Tube Cancer
Peritoneal Carcinoma
Endometrial Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Shannon Westin, MD specialize in?
Shannon Westin, MD focuses on Ovarian Cancer and Fallopian Tube Cancer. In particular, much of their work with Ovarian Cancer has involved Stage IV patients, or patients who are BRCA positive.
Is Shannon Westin, MD currently recruiting for clinical trials?
Yes, Shannon Westin, MD is currently recruiting for 3 clinical trials in Houston Texas. If you're interested in participating, you should apply.
Are there any treatments that Shannon Westin, MD has studied deeply?
Yes, Shannon Westin, MD has studied treatments such as Olaparib, Paclitaxel, Carboplatin.
What is the best way to schedule an appointment with Shannon Westin, MD?
Apply for one of the trials that Shannon Westin, MD is conducting.
What is the office address of Shannon Westin, MD?
The office of Shannon Westin, MD is located at: M D Anderson Cancer Center, Houston, Texas 77030 United States. This is the address for their practice at the M D Anderson Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.